摘要 |
The invention relates to polypeptides which inhibit the activity of glycogen synthase kinase-3 beta (GSK-3 beta) in vivo and which also activate wnt signaling. The polypeptides have an amino acid sequence which includes one or both of an axin/GSK-3 beta interaction domain (GID) and an axin/axin interaction domain (AID). These polypeptides are useful for treating a number of disorders (e.g. bipolar disorder, mania, depression, Alzheimer's disease, diabetes, and leukopenia) which are presently treated by administration of lithium. The invention also includes antibodies (including fragments of antibodies) which bind specifically with the polypeptides described in the disclosure, and to transgenic mice which comprise a transgene encoding such polypeptides.
|